Skip to content

CYPH CYPH Additional Paid-In Capital

Additional Paid-In Capital at other companies

Pfizer logo
PfizerPFE
$94.77B+1.0%
CNT
Canton Strategic Holdings, Inc. Common StockCNTN
$590.02M+1,425%
Ziff Davis logo
Ziff DavisZD
$454.33M-6.3%
Zscaler logo
ZscalerZS
$3.62B+22.4%
CTO
Citius Oncology, Inc.CTOR
$131.44M+47.2%
DTC
Datacentrex, Inc. DTCX
$94.05M+530%

Other financials

Income statement

See full
Revenue$375.0K
Operating income-$4.8M+69.7%
Net income-$77.2M-400%
EPS (diluted)-$0.46-24.3%

Balance sheet

See full
Cash & equivalents$6.7M-79.6%
Total debt$38.0K-75.3%
Total equity$84.4M+305%
Total assets$87.4M+151%

Cash flow

See full
Operating cash flow-$3.4M+76.3%

Valuation

See full
Market cap$65.19M-54.5%
Enterprise value$58.54M
P/S43.5×

Profitability

See full
Operating margin-2,761.7%
Net margin-2,705.8%

Returns & leverage

See full
Return on equity-108.2%-34.4pp
Debt / equity0.0×
Current ratio27.3×+24.9×

Where this comes from

Reported directly by CYPH in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: CYPH’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CYPH's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CYPH's additional paid-in capital?
CYPH (CYPH) reported additional paid-in capital of $624.08M in Q1 2026.
How has CYPH's additional paid-in capital changed year-over-year?
CYPH's additional paid-in capital increased by 23.9% year-over-year, from $503.72M to $624.08M.
What is the long-term trend for CYPH's additional paid-in capital?
Over 4 years (2021 to 2025), CYPH's additional paid-in capital has grown at a 13.5% compound annual growth rate (CAGR), from $371.64M to $616.22M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.